329044-14-6 Usage
Description
5-methyl-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one, also known as "4-(2-isopropoxybenzyl)-5-methyl-1,2-dihydro-3H-pyrazol-3-one," is a pyrazolone derivative with a molecular formula of C16H20N2O2. It is a chemical compound that holds potential pharmaceutical significance due to its potential applications and biological activities.
Used in Pharmaceutical Industry:
5-methyl-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one is used as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new medications.
Used in Drug Development Research:
5-methyl-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one is used as a subject of interest in drug development research due to its potential biological activities, such as anti-inflammatory and analgesic properties, which make it a promising candidate for further investigation and potential applications in medicinal chemistry.
Used in Treatment of Medical Conditions:
5-methyl-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one is studied for its potential use in the treatment of various medical conditions, highlighting its versatility and importance in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 329044-14-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,9,0,4 and 4 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 329044-14:
(8*3)+(7*2)+(6*9)+(5*0)+(4*4)+(3*4)+(2*1)+(1*4)=126
126 % 10 = 6
So 329044-14-6 is a valid CAS Registry Number.
329044-14-6Relevant articles and documents
AN IMPROVED PROCESS FOR THE PREPARATION REMOGLIFLOZIN ETABONATE OR PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE, HYDRATE THEREOF
-
, (2019/10/29)
The present invention relates to an improved process for the preparation of Remogliflozin, Remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof. The present invention relates to an improved process for preparation of Remog
GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
-
, (2008/06/13)
The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) gr
GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF
-
, (2008/06/13)
The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity on human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.
